Approximately 26–29% of PD patients who undergo DBS have a mutation in one of three genes: glucocerebrosidase (GBA), leucine-rich repeat kinase 2 (LRRK2), and parkin (PRKN) [2, 3]. Here, LRRK2 is linked to Parkinson disease.